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Abstract
Aim: To assess the effects of dapagliflozin plus saxagliptin plus metformin versus
glimepiride plus metformin on liver fat (proton density fat fraction) and visceral and
subcutaneous adipose tissue volumes over 52 weeks of treatment.
Materials and methods: This was a magnetic resonance imaging substudy of a
52-week, multicentre, randomized, double-blind, parallel-group trial that evaluated
the efficacy and safety of dapagliflozin 10 mg/day plus saxagliptin 5 mg/day versus
titrated glimepiride 1–6 mg (1, 2, 3, 4 or 6 mg) in 82 patients with type 2 diabetes
(HbA1c 7.5%–10.5%) on metformin ≥1500 mg/day background. Analyses were
exploratory and not controlled for multiplicity; P-values are nominal.
Results: Magnetic resonance imaging was performed on 59 patients; liver fat and
adipose tissue volumes were analysed for 59 and 57 patients, respectively. There was
a significant >30% reduction from baseline in liver fat (P = 0.007) and >10% reduction
in adipose tissue volumes (P < 0.01) with dapagliflozin plus saxagliptin plus metformin
at week 52 versus glimepiride plus metformin. In the full-study population,
dapagliflozin plus saxagliptin plus metformin decreased body weight and serum ala-
nine aminotransferase and aspartate aminotransferase levels over 52 weeks.
Conclusions: Dapagliflozin plus saxagliptin significantly decreased liver fat and adi-
pose tissue volume versus glimepiride, and reduced serum liver enzyme levels, indi-
cating a favourable metabolic profile of dapagliflozin plus saxagliptin in patients with
type 2 diabetes on metformin therapy.
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1 | INTRODUCTION
In patients with type 2 diabetes (T2D), weight loss is associated with
improvement in glycaemic control and reduction in cardiovascular (CV) risk
factors.1 T2D is a risk factor for nonalcoholic fatty liver disease (NAFLD),
which can progress to nonalcoholic steatohepatitis (NASH) and ultimately
cirrhosis and/or liver cancer.2 NAFLD has been defined by ≥5%
macrovesicular hepatocyte steatosis in the absence of significant alcohol
use, and is the most common cause of liver enzyme increases.3 Almost
three quarters of patients with T2D have NAFLD.4,5 Body weight reduc-
tion is one of the few measures that may prevent liver dysfunction.6,7
Given the well-known contribution of some commonly used T2D drugs,
such as sulfonylureas, to weight gain,8 alternative drug therapies are
desirable in patients with T2D with or at risk of concomitant liver disease.
Ectopic fat accumulation, including that of the liver, is related to
increased insulin resistance.9 Weight loss results in a reduction in liver fat
content.7 Reducing liver fat content in addition to weight loss may there-
fore help prevent liver disease progression in patients with T2D.
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that
reduces hyperglycaemia independent of insulin and also results in weight
loss and moderate blood pressure reduction in patients with T2D.10,11
Most of the weight loss associated with dapagliflozin has been shown to
be because of reductions in total body fat mass, abdominal visceral adipose
tissue (VAT) volume and subcutaneous adipose tissue (SAT) volume.12
Saxagliptin, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor,
also reduces HbA1c regardless of T2D stage, although with no clinically
significant effects on body weight.13 The fixed-dose combination
of dapagliflozin and saxagliptin was approved by the United States
Food and Drug Administration on February 28, 2017, for improving
glycaemic control in adults with T2D as an adjunct to diet and exercise
for those who have inadequate control with dapagliflozin or who are
already being treated with dapagliflozin and saxagliptin.14 Evidence
from phase 3 studies of dapagliflozin plus saxagliptin indicates that
weight loss observed with concomitant administration of dapagliflozin
and saxagliptin is similar to that of dapagliflozin alone.15,16 A global
phase 3b study (NCT02419612) found better efficacy (as shown by a
significantly decreased HbA1c) for dapagliflozin plus saxagliptin versus
the sulfonylurea glimepiride, both groups on metformin background, in
patients with T2D who had inadequate glycaemic control on metformin
alone.17 Safety profiles were similar between the two groups, although
the incidence of hypoglycaemia was lower in the dapagliflozin plus
saxagliptin group.17 Here, we report a substudy of this trial that used
magnetic resonance imaging (MRI) to determine liver fat deposition via
assessment of proton density fat fraction (PDFF), VAT volume and SAT
volume over 52 weeks of treatment.
2 | MATERIALS AND METHODS
2.1 | Study design and patients
This was a 52-week, international, multicentre, randomized, double-
blind, active-controlled, parallel-group, phase 3b study, with a
patient- and site-blinded, 104-week, long-term extension period
(Figure 1). At week 52, the least-squares mean change (95% confi-
dence interval [CI]) in HbA1c was −1.35% (−1.49, −1.22) for the
dapagliflozin plus saxagliptin group, and −0.98% (−1.12, −0.84) for
the glimepiride group, with similar rates of adverse events between
groups.17
The study was conducted at 87 centres in 10 countries beginning
on August 14, 2015 and comprised a 2-week screening period and a
2-week lead-in period. The study enrolled male or female patients (aged
≥18 years) with T2D, with HbA1c from ≥7.5% (58.5 mmol/mol)
to ≤10.5% (91.3 mmol/mol), with a body mass index (BMI) of
20.0–45.0 kg/m2 (inclusive) at enrolment, and on the same daily dose
of metformin ≥1500 mg for at least 8 weeks before enrolment. Key
exclusion criteria comprised clinical diagnosis of type 1 diabetes, malig-
nancy within 5 years of the screening visit (with the exception of
treated basal cell or treated squamous cell carcinoma), pregnancy, his-
tory of diabetic ketoacidosis and history of CV/vascular disease within
3 months of enrolment, including transient ischaemic attack or signifi-
cant cerebrovascular disease, and unstable or previously undiagnosed
arrhythmia. Patients with impaired renal function (creatinine clearance
<60 mL/min/1.73m2 [estimated by Cockcroft–Gault] or serum creati-
nine ≥1.5 mg/dL [132.6 μmol/L] in males or ≥1.4 mg/dL [123.8 μmol/
L] in females), severe hepatic insufficiency and/or significant abnormal
liver function (aspartate aminotransferase [AST] >3 × upper limit of
normal [ULN] and/or alanine aminotransferase [ALT] >3 × ULN),
F IGURE 1 Study design
(NCT02419612). DAPA, dapagliflozin;
GLIM, glimepiride; IR, instant release;
MET, metformin; SAXA, saxagliptin;
XR, extended release
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positive serologic evidence of current infectious liver disease, including
patients who were positive for hepatitis B viral antibody
immunoglobulin M, hepatitis B surface antigen and hepatitis C anti-
body, and/or history of current, acute or chronic pancreatitis were also
excluded. Further details are in the primary study article.17
2.2 | Interventions
Patients on metformin were randomly assigned, based on a randomi-
zation schedule stratified by site and using an interactive voice
response system, to the following double-blinded treatment groups in
a 1:1 ratio: dapagliflozin 10 mg plus saxagliptin 5 mg plus placebo,
each administered orally once daily (QD), or glimepiride 1–6 mg (spe-
cifically 1, 2, 3, 4 or 6 mg) plus placebo, each administered orally
QD. A fasting plasma glucose level of ≤270 mg/dL (15.0 mmol/L) was
required at randomization. The starting dose for glimepiride was 1 mg
QD, and was titrated stepwise using doses of 2, 3, 4 and 6 mg QD at
3-week intervals to a maximum of 6 mg QD. In patients for whom
titration was not medically indicated at week 3, reassessment for titra-
tion occurred at weeks 6, 9 and 12. Glimepiride could be downtitrated
in the event of hypoglycaemia.
2.3 | MRI substudy
The MRI substudy included patients from the full study who provided
informed consent, had no contraindications to MRI scanning, and had
a BMI of 20.0–40.0 kg/m2 (inclusive) at enrolment and a maximum
weight of 140 kg to accommodate MRI scanning. No other selection
criteria were applied for participation in the substudy. The MRI sub-
study was conducted at nine MRI centres in Hungary, the Czech
Republic, Poland, Russia and Sweden using GE HealthCare, Siemens
or Philips 1.5 or 3 T MRI scanners. MRI centres were selected based
on proximity to study sites willing to participate in the MRI substudy
and ability to perform PDFF measurements. To qualify, at each site a
healthy volunteer was scanned and PDFF values in adipose tissue and
muscle were checked to test that the PDFF measurements gave
reasonable results. No phantom was used because MRI-PDFF has
been shown to have excellent linearity, bias and precision across dif-
ferent field strengths, imager manufacturers and reconstruction
methods.18-20 The MRI substudy endpoint was 52 weeks. SAT and
VAT volumes were assessed using abdominal MRIs of patients. Liver
fat content was assessed using MRI-PDFF. This well-validated, nonin-
vasive imaging technique exploits the difference in MRI chemical shift
of triglyceride-based mobile protons from that of the water to enable
accurate quantitative liver fat assessment over the entire liver.21 In
adults with NAFLD, MRI-PDFF correlates highly with steatosis
grade22 and is a useful method in NASH clinical trials.21 MRI is a com-
prehensive tool to quantify fat, able to differentiate between VAT and
SAT with multidimensional images and to quantify ectopic fat safely
and with minimal examination time.23
2.4 | Assessments
The mean change from baseline in liver fat percentage by MRI-PDFF
and VAT and SAT volumes was assessed by MRI in both treatment
groups at week 52 in the subpopulation of patients in the MRI
substudy.
2.5 | Statistical analyses
Efficacy analyses were performed using the randomized patient dataset
(all randomized patients who received at least one dose of study medi-
cation) during the double-blind treatment period. Analysis for change in
serum liver enzyme levels was conducted on the treated patient
dataset (all patients who received at least one dose of study medication
during the study treatment period) during the short-term double-blind
treatment period. Analyses of change from baseline in liver fat percent-
age and VAT and SAT volumes in the MRI substudy were performed
using the analysis of covariance (ANCOVA) model based on last obser-
vation carried forward (LOCF) data. MRI analyses were not controlled
for multiplicity and nominal P-values are presented. Analysis of mean
change from baseline in total body weight was performed using a
longitudinal repeated measures model. All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | Patient disposition
Overall, 823 patients were enrolled. Of these, 444 entered the
double-blind treatment period; 227 were randomized to dapagliflozin
plus saxagliptin plus metformin and 217 were randomized to
glimepiride plus metformin (Figure S1). A total of 82 patients pro-
vided informed consent to participate in the MRI substudy, of whom
46 were in the dapagliflozin plus saxagliptin plus metformin treat-
ment group and 36 were in the glimepiride plus metformin treatment
group.
3.2 | Baseline demographics
Key baseline characteristics of the MRI substudy patients were well
balanced between the groups (Table 1).
3.3 | MRI substudy
MRI was performed on 59 patients and liver fat and adipose tissue
volume were analysed for 59 and 57 patients, respectively. There was
a significant >30% reduction from baseline in liver fat (P = 0.007) and
a >10% reduction in VAT volume (P < 0.001) and SAT volume
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(P = 0.006) with dapagliflozin plus saxagliptin plus metformin at week
52 versus glimepiride plus metformin (Table 2 and Figure 2).
3.4 | Full study
For patients in the dapagliflozin plus saxagliptin plus metformin treat-
ment group, body weight (mean ± standard deviation [SD]) reduced
from 90.8 ± 19.7 kg at baseline to 88.4 ± 18.1 kg at week 52. Patients
in the glimepiride plus metformin treatment group experienced weight
gain (mean ± SD) from 88.4 ± 17.0 kg at baseline to 90.6 ± 17.4 kg at
week 52. The decrease in mean total body weight from baseline to
week 52 in the dapagliflozin plus saxagliptin plus metformin treatment
group was significantly different from that in the glimepiride plus met-
formin treatment group (difference [95% CI], −4.1 kg [−4.8, −3.3];
P < 0.001). The difference in body weight between treatment groups
was evident at week 3 (difference [95% CI], −1.1 kg [−1.4, −0.9];
P < 0.001; Figure 3).
At week 52, there was a decrease from baseline in the serum levels
of both ALT and AST in the dapagliflozin plus saxagliptin plus metfor-
min treatment group. Although ALT and AST levels decreased they
remained within the normal range. By contrast, enzyme levels increased
in the glimepiride plus metformin treatment group (Figure S2).
4 | DISCUSSION
In this 52-week MRI substudy of a phase 3b, randomized, active-
controlled study, the SGLT2 inhibitor dapagliflozin, co-administered
with the DPP-4 inhibitor saxagliptin, significantly decreased liver fat
content, adipose tissue volume and body weight versus the sulfonyl-
urea glimepiride, with both groups on metformin background. Serum
liver enzyme levels in the dapagliflozin group were lower than in the
saxagliptin group, and although still in the normal range, did show a
decreasing trend. Elevated ectopic fat is a significant contributor to
the pathogenesis of T2D.24 Because liver fat correlates with increased
mortality from liver disease,25 the significant reduction in liver fat con-
tent observed in this substudy indicates that the combination of
dapagliflozin plus saxagliptin added to metformin could help prevent
the progression of liver disease in patients with T2D.
Although the mechanisms by which liver fat reduction occurs
with SGLT2 inhibition are not fully established, there are several pos-
sibilities. These include reduced hepatic lipogenesis, increased hepatic
insulin extraction as seen with dapagliflozin,26 improvements in insulin
concentrations and/or resistance, and/or, as seen in some animal
models, suppression of inflammatory cytokines and/or mitigation of
oxidative stress.27-29 Additionally, dapagliflozin's possible role as an
alpha cell secretagogue that has been shown to promote glucagon
secretion30 is consistent with its ability to reduce intrahepatic lipid
content.
TABLE 2 Liver fat and adipose tissue volumes over the 52-week,
double-blind treatment period for the magnetic resonance imaging
(MRI) substudy
Variable DAPA+SAXA+MET GLIM+MET P -value†
N 35 24
Liver fat, PDFF%
Baseline 14.3 (6.4) 13.7 (8.3)
Week 52 9.9 (7.1) 12.9 (8.6) 0.007
N 34 23
VAT, L
Baseline 3.6 (1.1) 2.9 (1.1)
Week 52 3.2 (1.1) 3.0 (1.1) < 0.001
SAT, L
Baseline 4.7 (2.2) 4.1 (1.8)
Week 52 4.2 (2.0) 4.1 (1.7) 0.006
Abbreviations: ANCOVA, analysis of covariance; DAPA, dapagliflozin;
GLIM, glimepiride; LOCF, last observation carried forward; LS, least
squares; MET, metformin; PDFF, proton density fat fraction; SAT,
subcutaneous adipose tissue; SAXA, saxagliptin; SD, standard deviation;
VAT, visceral adipose tissue.
All data are reported as mean (SD) unless specified otherwise.
†Nominal P-value for LS mean difference in change from baseline to week
52 between groups. Analysis of mean change from baseline in total body
weight was performed using a longitudinal repeated measures model.
Analyses of change from baseline in liver fat percentage and VAT and SAT
volumes in the MRI substudy were performed using the ANCOVA model
based on LOCF data.
TABLE 1 Demographics and baseline disease characteristics
(randomized patient dataset) for the MRI substudy
Characteristic
DAPA+SAXA
+MET (n = 46)
GLIM+MET
(n = 36)
Total
(N = 82)
Age, years 58.9 (8.2) 56.9 (10.0) 58.0 (9.0)
Female, n (%) 22 (47.8) 19 (52.8) 41 (50.0)
Weight, kg 94.4 (16.5) 90.9 (17.3) 92.9 (16.8)
BMI, kg/m2 32.9 (4.7) 32.3 (5.1) 32.6 (4.9)
BMI group,
kg/m2, n (%)
<25 1 (2.2) 3 (8.3) 4 (4.9)
≥25– <27 4 (8.7) 1 (2.8) 5 (6.1)
≥27– <30 11 (23.9) 8 (22.2) 19 (23.2)
≥30 30 (65.2) 24 (66.7) 54 (65.9)
Race, n (%)
White 46 (100.0) 36 (100.0) 82 (100.0)
Region, n (%)
Europe 46 (100.0) 36 (100.0) 82 (100.0)
Duration of T2D,
years
6.4 (5.8) 6.5 (6.4) 6.4 (6.0)
HbA1c, % 8.4 (0.8) 8.6 (0.9) 8.5 (0.9)
FPG, mg/dL 10.2 (3.1) 10.5 (2.6) 10.4 (2.8)
Abbreviations: BMI, body mass index; DAPA, dapagliflozin; FPG, fasting
plasma glucose; GLIM, glimepiride; MET, metformin; MRI, magnetic
resonance imaging; SAXA, saxagliptin; SD, standard deviation; T2D, type
2 diabetes.
All data are reported as mean (SD) unless specified otherwise. Includes all
patients who consented to be in the MRI substudy.
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There may also be several mechanisms by which reductions in
liver fat content could lead to therapeutic benefit in patients with
T2D. The strong association between VAT and liver fat content with
hepatic insulin resistance in patients with T2D31 suggests one possi-
bility. The liver fat reduction results we found are consistent with
those of other studies of dapagliflozin. In a 12-week, randomized con-
trolled study, dapagliflozin significantly reduced liver fat in patients
with T2D and NAFLD.32 In a 6-month Japanese study, dapagliflozin
significantly reduced liver size and hepatic fat accumulation in patients
with inadequately controlled T2D. However, the study's open-label
and nonrandomized design precludes firm conclusions.26 Liver
enzymes were decreased with empagliflozin treatment in the EMPA-
REG OUTCOME trial.33
Although the direct contribution of each drug in the dapagliflozin
plus saxagliptin combination to liver improvement could not be deter-
mined, a previous study with a DPP-4 inhibitor did not find a
F IGURE 3 Adjusted mean change from
baseline in total body weight during the 52-week,
double-blind treatment period†.
Body weight assessments collected after initiation
of rescue treatment or collected more than 8 days
after the last dose in the short-term, double-blind
treatment period were excluded from the analysis.
†Patients from the randomized patient dataset
with nonmissing baseline assessment at week
52 were included in this analysis. Baseline is
defined as patients in the randomized patient
dataset with nonmissing baseline assessment and
at least one postbaseline assessment. DAPA,
dapagliflozin; GLIM, glimepiride; MET, metformin;
SAXA, saxagliptin
F IGURE 2 Representation of liver magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) pre- and post-treatment.
(A) Pre- and post-treatment MRI-PDFF for dapagliflozin plus saxagliptin plus metformin and (B) pre- and post-treatment MRI-PDFF for
glimepiride plus metformin
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reduction in hepatic fibrosis or steatosis in patients with T2D,34
suggesting that the beneficial liver effects observed in the current
study were a result of dapagliflozin. However, significant reductions in
body weight, VAT volume and liver fat content assessed by MRI-
PDFF were found with 26-week DPP-4 inhibitor treatment in patients
with T2D and NAFLD.35 Baseline DPP-4 activity has been reported to
be higher in insulin-resistant patients with NAFLD than in healthy
controls,36 and a small uncontrolled study reported a significant
decrease in hepatic lipid content after 6 months of vildagliptin or
sitagliptin treatment, although only in females.37
Elevated ALT levels sometimes indicate the presence of NAFLD,
and in NAFLD cases with normal liver enzyme levels, assessment of
liver fibrosis markers is recommended.2,38 In the current study, ALT
levels decreased in the dapagliflozin plus saxagliptin versus glimepiride
treatment group. SGLT2 inhibitors have been shown to result in sig-
nificantly greater reductions in ALT levels than incretin-based drugs in
patients with T2D,39 lending support to the notion that the ALT
decreases observed in the current study were primarily attributable to
dapagliflozin.
The weight loss observed with dapagliflozin plus saxagliptin was
consistent with that observed in previous studies.16 The difference in
weight loss between the treatment groups was evident by week
3, suggesting that the trend towards weight maintenance or decrease
among patients receiving dapagliflozin plus saxagliptin versus those
receiving glimepiride is rapid and sustainable. However, weight loss
alone may not be sufficient to entail a reduction in liver fat content.
This is supported by the fact that glucagon-like peptide-1 receptor
agonism40 and thiazolidinedione treatment41-43 in patients with T2D
have been shown to result in liver fat reductions independent of
effects on body weight. In the current study, at least some of the
reduction in liver fat content with dapagliflozin plus saxagliptin com-
pared with glimepiride could have been because of a reduction in
body weight; however, because glimepiride resulted in weight gain, it
is not possible to compare the differential effects of the two treat-
ment groups with respect to liver fat reduction. Although the reduc-
tion in liver fat in the current study was accompanied by overall
weight loss, there is some evidence to suggest that reductions in liver
fat with SGLT2 inhibition may be independent of SGLT2 inhibitors’
effects on weight loss.44 We did not, however, investigate if this was
true for dapagliflozin.
In conclusion, dapagliflozin co-administered with saxagliptin sig-
nificantly decreased liver fat and adipose tissue volume versus
glimepiride. The decrease in liver fat and adipose tissue volume was
accompanied by a significant reduction in body weight and a reduc-
tion in the levels of serum liver enzymes for patients in the full study
in the dapagliflozin plus saxagliptin group. These results indicate a
favourable metabolic profile of dapagliflozin plus saxagliptin versus
glimepiride in patients with T2D.
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